Pareto maintains its Hold recommendation and the target price of SEK 1.7 for the medtech company Synthetic MR after the company this morning announced a rights issue of SEK 32.8 million. "We expect the share to trade lower in the short term, but for long-term investors the new share issue should be seen as positive, as it secures funding for the company’s planned commercial expansion and ongoing operations," it says.